Fig. 2: Minimal residual disease (MRD) status and outcomes. | Nature Communications

Fig. 2: Minimal residual disease (MRD) status and outcomes.

From: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Fig. 2

a Longitudinal MRD assessments by NGS in peripheral blood in the Ven-Obi arm and b in the Clb-Obi arm, c landmark PFS according to MRD status in the Ven-Obi arm and d in the Clb-Obi arm, e landmark OS according to MRD status in the Ven-Obi arm and f in the Clb-Obi arm, g landmark PFS according to MRD status in the Ven-Obi arm and h in the Clb-Obi arm; ‘Not available’ indicates patients without an end of treatment MRD status, due to earlier withdrawal or missing/unevaluable samples.

Back to article page